Summary & Overview
HCPCS J2730: Pralidoxime Chloride Injection, Up to 1 gm
HCPCS Level II code J2730 denotes the injection of pralidoxime chloride, up to 1 gram, an antidotal therapy used in cases of organophosphate or nerve agent exposure. Nationally, this code is relevant for emergency and inpatient billing where rapid parenteral administration of antidotes is required. It matters for hospitals, emergency medical services, and payers because accurate coding affects clinical documentation, inventory management, and claim adjudication for high-acuity, low-frequency treatments.
Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for J2730, payer coverage considerations, and coding relationships. The publication summarizes typical sites of service, expected use cases in acute care, and common modifiers used in claims (modifier list provided separately). It also outlines what documentation is typically needed to support medical necessity for antidote administration and highlights areas where policy updates or payer-specific rules commonly occur.
This resource is intended for billing professionals, clinical coders, and hospital administrators seeking a focused reference on proper use of HCPCS Level II code J2730, including practical notes on claim preparation and the types of benchmarks and policy points to review with each payer.
Billing Code Overview
HCPCS Level II code J2730 describes an injection of pralidoxime chloride, up to 1 gm. This entry represents the pharmaceutical administration of pralidoxime chloride, an antidote used to reactivate acetylcholinesterase following organophosphate or certain nerve agent poisoning.
-
Service type: Medication injection (antidote therapy)
-
Typical site of service: Emergency department, inpatient hospital, or other acute care settings where parenteral antidote administration is performed
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 42-year-old male is brought to the emergency department by emergency medical services after suspected organophosphate pesticide exposure at a farm. He is diaphoretic, salivating, bradycardic, and has increased bronchial secretions with wheezing. The toxicology team evaluates and determines treatment with atropine and an oxime is required. The clinician orders J2730 (injection, pralidoxime chloride, up to 1 gm) to be administered intravenously. Nursing prepares the medication, documents lot number and amount administered, and monitors vital signs, respiratory status, and neuromuscular response during and after infusion. The patient receives repeated doses per toxicology protocol; each administered vial is billed using J2730 with appropriate administration documentation recorded in the medical record.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Use when no modifier applies; default reporting when no special circumstance exists. |
22 | Increased procedural services |